Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases

References

• Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998; 55:1091 - 7; http://dx.doi.org/10.1016/S0006-2952(97)00682-5; PMID: 9605432
   PubMed Web of Science ®Google Scholar
• Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274 - 81; http://dx.doi.org/10.1016/S0959-8049(98)00058-6; PMID: 9849491
   PubMed Web of Science ®Google Scholar
• Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45:291 - 7; http://dx.doi.org/10.1007/s002800050043; PMID: 10755317
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998; 58:685 - 90; PMID: 9485021
   PubMed Web of Science ®Google Scholar
• Ishitsuka H. Capecitabine: preclinical pharmacology studies. Invest New Drugs 2000; 18:343 - 54; http://dx.doi.org/10.1023/A:1006497231579; PMID: 11081570
   PubMed Web of Science ®Google Scholar
• Ninomiya I, Terada I, Yoshizumi T, Takino T, Nagai N, Morita A, et al. Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum. Int J Cancer 2004; 112:135 - 42; http://dx.doi.org/10.1002/ijc.20360; PMID: 15305385
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al, Xeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097 - 106; PMID: 11689577
   PubMed Web of Science ®Google Scholar
• Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282 - 92; PMID: 11304782
   PubMed Web of Science ®Google Scholar
• Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352:2696 - 704; http://dx.doi.org/10.1056/NEJMoa043116; PMID: 15987918
   PubMed Web of Science ®Google Scholar
• Teng LS, Jin KT, He KF, Wang HH, Cao J, Yu DC. Advances in combination of antiangiogenic agents targeting VEGF-binding and conventional chemotherapy and radiation for cancer treatment. J Chin Med Assoc 2010; 73:281 - 8; http://dx.doi.org/10.1016/S1726-4901(10)70062-9; PMID: 20603084
   PubMed Web of Science ®Google Scholar
• Jin K, He K, Teng F, Li G, Wang H, Han N, et al. FP3: a novel VEGF blocker with antiangiogenic effects in vitro and antitumour effects in vivo. Clin Transl Oncol 2011; 13:878 - 84; http://dx.doi.org/10.1007/s12094-011-0749-z; PMID: 22126731
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang J, Yan M, Li H, Yang C, Yu D. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys. Mol Vis 2008; 14:37 - 49; PMID: 18246030
   PubMed Web of Science ®Google Scholar
• Zhang M, Yu D, Yang C, Xia Q, Li W, Liu B, et al. The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res 2009; 26:204 - 10; http://dx.doi.org/10.1007/s11095-008-9718-9; PMID: 18854954
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang J, Yan M, Luo D, Zhu W, Kaiser PK, et al, KH902 Phase 1 Study Group. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology 2011; 118:672 - 8; http://dx.doi.org/10.1016/j.ophtha.2010.08.008; PMID: 21146224
   PubMed Web of Science ®Google Scholar
• Yu DC, Lee JS, Yoo JY, Shin H, Deng H, Wei Y, et al. Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects. [Epub ahead of print] Mol Ther 2012; 20:938 - 47; http://dx.doi.org/10.1038/mt.2011.285; PMID: 22273580
   PubMed Web of Science ®Google Scholar
• Jin K, He K, Han N, Li G, Wang H, Xu Z, et al. Establishment of a PDTT xenograft model of gastric carcinoma and its application in personalized therapeutic regimen selection. Hepatogastroenterology 2011; 58:1814 - 22; http://dx.doi.org/10.5754/hge11136; PMID: 21940303
   PubMed Web of Science ®Google Scholar
• Jin K, Li G, Cui B, Zhang J, Lan H, Han N, et al. Assessment of a novel VEGF targeted agent using patient-derived tumor tissue xenograft models of colon carcinoma with lymphatic and hepatic metastases. PLoS One 2011; 6:e28384; http://dx.doi.org/10.1371/journal.pone.0028384; PMID: 22164281
   PubMedGoogle Scholar
• Kolinsky K, Zhang YE, Dugan U, Heimbrook D, Packman K, Higgins B. Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts. Anticancer Res 2009; 29:91 - 8; PMID: 19331137
   PubMed Web of Science ®Google Scholar
• Yanagisawa M, Fujimoto-Ouchi K, Yorozu K, Yamashita Y, Mori K. Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models. Oncol Rep 2009; 22:241 - 7; PMID: 19578762
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013 - 9; http://dx.doi.org/10.1200/JCO.2007.14.9930; PMID: 18421054
   PubMed Web of Science ®Google Scholar
• Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4:1013 - 9; PMID: 9563897
   PubMed Web of Science ®Google Scholar
• Endo M, Shinbori N, Fukase Y, Sawada N, Ishikawa T, Ishitsuka H, et al. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 1999; 83:127 - 34; http://dx.doi.org/10.1002/(SICI)1097-0215(19990924)83:1<127::AID-IJC22>3.0.CO;2-6; PMID: 10449619
   PubMed Web of Science ®Google Scholar
• Sawada N, Kondoh K, Mori K. Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts. Oncol Rep 2007; 18:775 - 8; PMID: 17786335
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7:987 - 9; http://dx.doi.org/10.1038/nm0901-987; PMID: 11533692
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58 - 62; http://dx.doi.org/10.1126/science.1104819; PMID: 15637262
   PubMed Web of Science ®Google Scholar
• Jin K, Teng L, Shen Y, He K, Xu Z, Li G. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol 2010; 12:473 - 80; http://dx.doi.org/10.1007/s12094-010-0540-6; PMID: 20615824
   PubMed Web of Science ®Google Scholar
• Jin KT, He KF, Li GL, Teng LS. Personalized cancer therapy using a patient-derived tumor tissue xenograft model: a translational field worthy of exploring further?. Pers Med 2010; 7:597 - 606; http://dx.doi.org/10.2217/pme.10.48
   PubMed Web of Science ®Google Scholar
• Nishida M, Hino A, Mori K, Matsumoto T, Yoshikubo T, Ishitsuka H. Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull 1996; 19:1407 - 11; http://dx.doi.org/10.1248/bpb.19.1407; PMID: 8951154
   PubMed Web of Science ®Google Scholar